Dr. Yamada noted that 2 mg/day is “a relatively low dose” and so avoiding glucocorticosteroid therapy in those at risk of sarcopenia, particularly those with a low fat mass, may be something to consider.
The study did not receive commercial funding, and Dr. Yamada had no conflicts of interest to disclose.
SOURCE: Yamada Y et al. Ann Rheum Dis. 2018;77(Suppl 2):308-9. Abstract THU0181.